Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.

Abstract:

PURPOSE:S-1 has systemic activity for locally advanced pancreatic cancer (LAPC). Here, the efficacy and safety of induction gemcitabine (GEM) and S-1 (GS) followed by chemoradiotherapy (CRT) and systemic chemotherapy using S-1 for LAPC were assessed. METHODS:The treatment consisted of four cycles of induction GS (S-1 60, 80, or 100 mg/day based on body surface area for 14 days every 3 weeks plus GEM 1000 mg/m2 on days 8 and 15), followed by S-1 (80, 100, or 120 mg/day based on body surface area on days 1-14 and 22-35) and concurrent radiotherapy (50.4 Gy in 28 fractions). Maintenance chemotherapy with S-1 was started 1-4 weeks after CRT until disease progression or unacceptable toxicity was observed. The primary endpoint was 1-year survival. RESULTS:A total of 30 patients with LAPC were enrolled. The median survival and progression-free survival were 21.3 and 12.7 months, respectively. Overall survival rates at 1, 2, 3, and 4 years were 73.3, 36.7, 23.3, and 16.7%, respectively. The median survival of 23 patients who received CRT was 22.9 months, with a 3-year survival rate of 30.4%. The two most common grade 3 or 4 adverse events during induction GS were neutropenia (63.3%) and biliary tract infection (20%). Toxicities during CRT or maintenance chemotherapy were generally mild. CONCLUSIONS:This regimen was feasible and highly active resulting in encouraging survival in patients with LAPC. Further investigations are warranted to elucidate the effectiveness of this treatment strategy in future studies. Clinical trials information: UMIN000006332.

authors

Sudo K,Hara R,Nakamura K,Kita E,Tsujimoto A,Yamaguchi T

doi

10.1007/s00280-017-3350-5

subject

Has Abstract

pub_date

2017-07-01 00:00:00

pages

195-202

issue

1

eissn

0344-5704

issn

1432-0843

pii

10.1007/s00280-017-3350-5

journal_volume

80

pub_type

杂志文章
  • Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU.

    abstract::AspCNU and SarCNU are two amino acid amide congeners (L-asparaginamide and sarcosinamide congeners) of chloroethylnitrosoureas. The in vitro myelotoxicity of these agents compared with BCNU at 1-8 micrograms/ml was determined in bone marrow cells from normal volunteers in the CFU-C assay. AspCNU and SarCNU were signif...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00434356

    authors: Panasci LC,Dufour M,Chevalier L,Isabel G,Lazarus P,McQuillan A,Arbit E,Brem S,Feindel W

    更新日期:1985-01-01 00:00:00

  • A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma.

    abstract::Thirty-five patients with a diagnosis of non-Hodgkin's lymphoma of low histological grade were treated with 2 X 10(6)/m2 of human rDNA alpha 2 IFN-a2 by subcutaneous injection. Treatment was continued until progressive disease was documented or one year of therapy had been given. None of the patients had to stop treat...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00253065

    authors: Wagstaff J,Loynds P,Crowther D

    更新日期:1986-01-01 00:00:00

  • Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.

    abstract:PURPOSE:To evaluate the outcomes of intraperitoneal chemotherapy (IP) compared with those of intravenous chemotherapy (IV) in patients with advanced ovarian cancer after neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS). METHODS:Patients with advanced epithelial ov...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-018-3591-y

    authors: Lee J,Curtin JP,Muggia FM,Pothuri B,Boyd LR,Blank SV

    更新日期:2018-07-01 00:00:00

  • Chemotherapy in the management of invasive bladder cancer. A review.

    abstract::In this review of the management of invasive carcinoma of the bladder the results of primary and systemic therapies are evaluated in the light of the natural history of the disease. The clinical and pathological causes of treatment failure are assessed in an attempt to identify new approaches that may be used in the f...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/BF00254978

    authors: Bush H,Thatcher N,Barnard R

    更新日期:1979-01-01 00:00:00

  • Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme.

    abstract:PURPOSE:Although chemotherapeutic protocols that include chloroethylnitrosoureas (CENUs), such as 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) and 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU), have been a mainstay of treatment for glioblastomas, the clinical outcomes ha...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050023

    authors: Narita Y,Asai A,Kuchino Y,Kirino T

    更新日期:2000-01-01 00:00:00

  • Anti-liver cancer effect and the mechanism of arsenic sulfide in vitro and in vivo.

    abstract:PURPOSE:This study aimed at investigating the anti-tumor effect of arsenic sulfide (As2S2) against liver cancer both in vivo and in vitro and to elucidate its underlying mechanisms. METHODS:Cell viability of the human hepatocellular carcinoma cell lines SMMC-7721, BEL-7402, HepG2 were measured by CCK-8 assay. The effe...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-018-3755-9

    authors: Wang S,Zhang C,Li Y,Li P,Zhang D,Li C

    更新日期:2019-03-01 00:00:00

  • Sodium thiosulfate fails to increase the therapeutic index of intravenously administered cis-diamminedichloroplatinum (II) in mice bearing murine and human tumors.

    abstract::Intravenous (i.v.) administration of sodium thiosulfate reduces the toxicity of cis-diamminedichloroplatinum (II) (CDDP). This effect, which allows the use of increased CDDP doses, has been exploited clinically in the intraperitoneal (i.p.) treatment of intraabdominal tumors. Recently, attempts have been made to treat...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00257358

    authors: Aamdal S,Fodstad O,Pihl A

    更新日期:1988-01-01 00:00:00

  • Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy.

    abstract:PURPOSE:Many patients with non-small cell lung cancer (NSCLC) are eligible only for palliative radiation (RT) at presentation. This study was designed to assess the feasibility of adding the anti-EGFR monoclonal antibody nimotuzumab to palliative thoracic RT. METHODS:Patients with stage IIB, III or IV NSCLC considered...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-010-1379-9

    authors: Bebb G,Smith C,Rorke S,Boland W,Nicacio L,Sukhoo R,Brade A

    更新日期:2011-04-01 00:00:00

  • A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.

    abstract:PURPOSE:This phase I trial evaluated the maximum tolerated dose, safety and preliminary efficacy of lapatinib, a HER1, HER2 dual kinase inhibitor plus bortezomib, a proteasome inhibitor, in adult patients with advanced malignancies. METHODS:Patients were enrolled in a standard 3 + 3 design with lapatinib (L) 750, 1000...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03947-7

    authors: Lynce F,Wang H,Petricoin EF,Pohlmann PR,Smaglo B,Hwang J,He AR,Subramaniam DS,Deeken J,Marshall J,Pishvaian MJ

    更新日期:2019-11-01 00:00:00

  • Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus.

    abstract::A total of 26 evaluable patients presenting with advanced or metastatic squamous-cell carcinoma of the esophagus were entered in a phase II trial to assess the single-agent activity of etoposide. Etoposide was given at a dose of 200 mg/m2 on 3 consecutive days every 3 weeks. Five patients (19%) achieved a partial resp...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00685952

    authors: Harstrick A,Bokemeyer C,Preusser P,Köhne-Wömpner CH,Meyer HJ,Stahl M,Knipp H,Schmoll HJ,Wilke H

    更新日期:1992-01-01 00:00:00

  • Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin.

    abstract::Our previous randomised trial in patients with advanced ovarian cancer indicated a significant response and survival advantage for those receiving high-dose (100 mg/m2) as compared with low-dose (50 mg/m2) cisplatin in combination with cyclophosphamide (750 mg/m2). However, this was accompanied by more toxicity; perip...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s002800050723

    authors: Cassidy J,Paul J,Soukop M,Habeshaw T,Reed NS,Parkin D,Kaye SB

    更新日期:1998-01-01 00:00:00

  • Extensive stage small cell carcinoma of the bronchus. A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide.

    abstract::Fifty-four patients whose disease had been staged as extensive small cell carcinoma of the bronchus were randomised to receive either CAV1 (cyclophosphamide 600 mg m-2 i.v., adriamycin 50 mg m-2 i.v., given on day 1, and etoposide 500 mg m-2 p.o. given on day 3) or CAV5 (cyclophosphamide and adriamycin given as for CA...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00254574

    authors: Mead GM,Thompson J,Sweetenham JW,Buchanan RB,Whitehouse JM,Williams CJ

    更新日期:1987-01-01 00:00:00

  • Tumor resensitization to erlotinib following brief substitution of cetuximab.

    abstract::Targeted inhibition of epidermal growth factor receptors (EGFR) is becoming a standard anticancer treatment in defined clinical scenarios. EGFR inhibition may be achieved either by small-molecule orally bioavailable tyrosine kinase inhibitors, such as gefitinib or erlotinib, or else by large-molecule receptor antibodi...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-008-0698-6

    authors: Epstein RJ,Leung TW

    更新日期:2008-11-01 00:00:00

  • Oral levonantradol in the control of cancer chemotherapy-induced emesis.

    abstract::A dose-ranging study with oral levonantradol was performed in 20 cancer patients. The optimum oral dose which attenuated vomiting accompanying chemotherapy was 1 mg 4-hourly. Side-effects comprised dizziness, confusion, euphoria, drowsiness, and difficulty in concentrating. There was no cardiovascular toxicity. Overal...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00257422

    authors: Welsh J,Stuart F,Sangster G,Milstead R,Kaye S,Cash H,Charlton D,Calman K

    更新日期:1983-01-01 00:00:00

  • ASNA1, an ATPase targeting tail-anchored proteins, regulates melanoma cell growth and sensitivity to cisplatin and arsenite.

    abstract:PURPOSE:ASNA1 is homologous to E. coli ArsA, a well characterized ATPase involved in efflux of arsenite and antimonite. Cells resistant to arsenite and antimonite are cross-resistant to the chemotherapeutic drug cisplatin. ASNA1 is also an essential ATPase for the insertion of tail-anchored proteins into ER membranes a...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-008-0762-2

    authors: Hemmingsson O,Zhang Y,Still M,Naredi P

    更新日期:2009-02-01 00:00:00

  • Antitumor activity of treosulfan in human lung carcinomas.

    abstract::Treosulfan (L-threitol 1,4-bismethanesulfonate, Ovastat) is an alkylating agent and a structural analogue of busulfan. It has been established in the clinical chemotherapy of human ovarian carcinomas for several years and has additionally been shown to be effective against xenografted human breast carcinomas. No other...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00688319

    authors: Köpf-Maier P,Sass G

    更新日期:1996-01-01 00:00:00

  • Modulation of mitomycin C-induced multidrug resistance in vitro.

    abstract::A series of in vitro cytotoxicity studies were performed to achieve pharmacologic reversal of resistance to the alkylating agent mitomycin (MMC) in L-1210 leukemia cells. A multidrug-resistant (MDR), P-glycoprotein-positive cell line, RL-1210/.1 [11], was exposed to potential MDR modulators in the absence or presence ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685114

    authors: Dorr RT,Liddil JD

    更新日期:1991-01-01 00:00:00

  • Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.

    abstract:OBJECTIVES:The aim of this phase II study was to evaluate the response rate to gemcitabine combined with cisplatin in patients with locally advanced, metastatic or recurrent biliary tract cancer who had received no prior chemotherapy. METHODS:The treatment consisted of cisplatin 70 mg/m(2) in intravenous infusion foll...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-007-0444-5

    authors: Lee J,Kim TY,Lee MA,Ahn MJ,Kim HK,Lim HY,Lee NS,Park BJ,Kim JS,Korean Cancer Study Group.

    更新日期:2008-01-01 00:00:00

  • D-dimer increase: an unfavorable factor for patients with primary liver cancer treated with TACE.

    abstract:PURPOSE:To explore the clinical significance of plasma D-dimer increase for transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC). METHODS:The clinical data of 80 PLC patients who underwent TACE in our hospital from January 2015 to January 2017 were collected, including the plasma...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03778-6

    authors: Chen X,Chang Z,Liu Z

    更新日期:2019-04-01 00:00:00

  • Metronomics chemotherapy: time for computational decision support.

    abstract::Over the last decade, metronomic chemotherapy has been increasingly considered as an attractive strategy for treating cancer in a variety of settings. Beside pharmaco-economic considerations making metronomics a unique opportunity in low- or middle-income countries, revisiting dosing schedules using continuous low dos...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00280-014-2546-1

    authors: Barbolosi D,Ciccolini J,Meille C,Elharrar X,Faivre C,Lacarelle B,André N,Barlesi F

    更新日期:2014-09-01 00:00:00

  • Hypocrellins as photosensitizers for photodynamic therapy: a screening evaluation and pharmacokinetic study.

    abstract::Hypocrellin compounds were selected as potential photosensitizers for photodynamic therapy (PDT) owing to their high quantum yields of singlet oxygen (1O2), and facility for site-directed chemical modification to enhance phototoxicity, pharmacokinetics, solubility, and light absorption in the red spectral region, amon...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050395

    authors: Estey EP,Brown K,Diwu Z,Liu J,Lown JW,Miller GG,Moore RB,Tulip J,McPhee MS

    更新日期:1996-01-01 00:00:00

  • Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.

    abstract:PURPOSE:Trametinib is a reversible, selective inhibitor of the mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and 2 (MEK2). Cardiotoxicity (congestive heart failure, decreased heart rate, left ventricular dysfunction, and hypertension) related to trametinib is an infrequent, but serious, adverse event...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-016-3090-y

    authors: Patnaik A,Tolcher A,Papadopoulos KP,Beeram M,Rasco D,Werner TL,Bauman JW,Scheuber A,Cox DS,Patel BR,Zhou Y,Hamid M,Schramek D,Sharma S

    更新日期:2016-09-01 00:00:00

  • Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer.

    abstract:OBJECTIVES:Concurrent chemoradiotherapy (CRT) is the current standard of treatment for anal squamous carcinoma. However, local or metastatic recurrences remain significant after CRT with 5-fluorouracil (5-FU) and mitomycin C (MMC). Therefore, the present study evaluated the feasibility and efficacy of adding cisplatin ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-016-3185-5

    authors: Lee IH,Lee SJ,Kang BW,Chae YS,Baek D,Hwang S,Kim HJ,Park SY,Park JS,Choi GS,Kim JC,Kim JG

    更新日期:2016-12-01 00:00:00

  • Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay.

    abstract::A human tumor clonogenic assay (HTCA) has been used to evaluate standard and experimental anticancer drugs with respect to their inhibition of clonogenicity of both fresh human cancers and human tumor cell lines. By comparing the inhibitory effect on tumor colony-forming unit (TCFU) growth of 1-h and continuous drug e...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00256533

    authors: Ludwig R,Alberts DS,Miller TP,Salmon SE

    更新日期:1984-01-01 00:00:00

  • Correction to: Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells.

    abstract::Unfortunately, the online published article has error in Figure 4. The correct Figure 4 is given here. ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s00280-018-3590-z

    authors: Zhang Q,Li XT,Chen Y,Chen JQ,Zhu JY,Meng Y,Wang XQ,Li Y,Geng SS,Xie CF,Wu JS,Zhong CY,Han HY

    更新日期:2018-06-01 00:00:00

  • Effect of cyclosporine on colchicine partitioning in the rat liver.

    abstract::Colchicine is secreted into bile as a major pathway of elimination. Cyclosporine (CsA) inhibits colchicine biliary secretion. In the present study, the effects of cyclosporine and its vehicle (cremophor) on the partitioning of colchicine across the liver were studied. CsA decreased the colchicine bile/plasma ratio fro...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685886

    authors: Speeg KV,Maldonado AL

    更新日期:1993-01-01 00:00:00

  • Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.

    abstract::Cell lines resistant to five antitumor alkylating agents (CDDP, PAM, 4-HC, HN2, and BCNU) were developed from five parental human tumor lines representative of solid tumors with a range of sensitivities to antitumor alkylating agents. The parental cell lines were SCC-25 squamous carcinoma of the head and neck, MCF-7 b...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685328

    authors: Frei E 3rd,Holden SA,Gonin R,Waxman DJ,Teicher BA

    更新日期:1993-01-01 00:00:00

  • Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.

    abstract:PURPOSE:To describe the natural growth of vestibular schwannoma in patients with neurofibromatosis type 2 and to predict tumor volume evolution in patients treated with bevacizumab and everolimus. METHODS:Clinical data, including longitudinal tumor volumes in patients treated by bevacizumab (n = 13), everolimus (n = 7...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-016-3046-2

    authors: Ouerdani A,Goutagny S,Kalamarides M,Trocóniz IF,Ribba B

    更新日期:2016-06-01 00:00:00

  • Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide.

    abstract:PURPOSE:Thalidomide has recently shown significant promise in the treatment of some types of cancer, and trials in combination with conventional chemotherapy are being undertaken. We wished to determine whether thalidomide potentiated the effect of cyclophosphamide, a commonly used cytotoxic drug, in a murine tumour mo...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-002-0482-y

    authors: Ding Q,Kestell P,Baguley BC,Palmer BD,Paxton JW,Muller G,Ching LM

    更新日期:2002-09-01 00:00:00

  • Oestrogen receptors and response to cytotoxic chemotherapy in advanced breast cancer.

    abstract::Of 54 patients with advanced breast cancer, 21/37 (57%) with oestrogen receptor-positive (ER+) tumours and 11/17 (65%) with oestrogen receptor-negative (ER-) tumours responded to cytotoxic chemotherapy. These data and a survey of the literature indicate that oestrogen receptor status is not a determinant of response t...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00255457

    authors: Rubens RD,King RJ,Sexton S,Minton MJ,Hayward JL

    更新日期:1980-01-01 00:00:00